These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34811955)

  • 21. Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.
    Kaur Mukker J; Dukes G; Wang L; Huh S; Khudyakov P; Nishihara M; Chen C
    Clin Transl Sci; 2022 May; 15(5):1281-1290. PubMed ID: 35218604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ubrogepant to treat migraine.
    Dhir A
    Drugs Today (Barc); 2020 Jul; 56(7):459-467. PubMed ID: 32648856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications.
    Goadsby PJ; Blumenfeld AM; Lipton RB; Dodick DW; Kalidas K; M Adams A; Jakate A; Liu C; Szegedi A; Trugman JM
    Cephalalgia; 2021 Apr; 41(5):546-560. PubMed ID: 33241721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ubrogepant: First Approval.
    Scott LJ
    Drugs; 2020 Feb; 80(3):323-328. PubMed ID: 32020557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.
    Li CC; Voss T; Kowalski K; Yang B; Kleijn HJ; Jones CJ; Bosch R; Michelson D; DeAngelis M; Xu Y; Xie I; Kothare PA
    Clin Transl Sci; 2020 May; 13(3):482-490. PubMed ID: 31758661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling.
    Li CC; Dockendorf M; Kowalski K; Yang B; Xu Y; Xie I; Kleijn HJ; Bosch R; Jones C; Thornton B; Marcantonio EE; Voss T; Bateman KP; Kothare PA
    J Clin Pharmacol; 2018 Mar; 58(3):294-303. PubMed ID: 29136283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
    MacGregor EA; Hutchinson S; Lai H; Dabruzzo B; Yu SY; Trugman JM; Ailani J
    Headache; 2023 Sep; 63(8):1135-1144. PubMed ID: 37655536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the pharmacokinetic interaction between lesogaberan (AZD3355) and esomeprazole in healthy subjects.
    Niazi M; Silberg DG; Miller F; Ruth M; Holmberg AA
    Drugs R D; 2010; 10(4):243-51. PubMed ID: 21171670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world efficacy, tolerability, and safety of ubrogepant.
    Chiang CC; Arca KN; Dunn RB; Girardo ME; Quillen JK; Dodick DW; Starling AJ
    Headache; 2021 Apr; 61(4):620-627. PubMed ID: 33547676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.
    Voss T; Lipton RB; Dodick DW; Dupre N; Ge JY; Bachman R; Assaid C; Aurora SK; Michelson D
    Cephalalgia; 2016 Aug; 36(9):887-98. PubMed ID: 27269043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial.
    Jakate A; Boinpally R; Butler M; Lu K; McGeeney D; Periclou A
    Clin Pharmacol Ther; 2020 Apr; 107(4):1014-1022. PubMed ID: 31628854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials.
    Blumenfeld AM; Knievel K; Manack Adams A; Severt L; Butler M; Lai H; Dodick DW
    Adv Ther; 2022 Jan; 39(1):692-705. PubMed ID: 34874514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. To Probe the Binding Interactions between Two FDA Approved Migraine Drugs (Ubrogepant and Rimegepant) and Calcitonin-Gene Related Peptide Receptor (CGRPR) Using Molecular Dynamics Simulations.
    Leung L; Liao S; Wu C
    ACS Chem Neurosci; 2021 Jul; 12(14):2629-2642. PubMed ID: 34184869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
    Xu H; O'Gorman M; Matschke K; Boutros T; Brega N; Tan W; Bello A
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):34-42. PubMed ID: 34825782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers.
    Niazi M; Andersson T; Nauclér E; Sundin M; Naesdal J
    Int J Clin Pharmacol Ther; 2009 Sep; 47(9):564-9. PubMed ID: 19761715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
    Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
    Boinpally R; McGeeney D; Borbridge L; Trugman J
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
    Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.